Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698554 · ClinicalTrials.gov registry record · Phase 3
Bimatoprost in the Treatment of Eyelash Hypotrichosis
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 464
- Enrollment target
NCT01698554: Completed Phase 3 study, sponsored by Allergan.
NCT01698554 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 464 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01698554, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 464 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).
Primary Outcome
The investigator evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.
Interventions
- DRUG bimatoprost formulation A solution
- DRUG bimatoprost solution 0.03 %
- DRUG vehicle of bimatoprost formulation A solution
- DRUG vehicle of bimatoprost solution 0.03 %
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
What the finished NCT01698554 record still lists
NCT01698554 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which bimatoprost formulation A solution is the first listed.
NCT01698554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01698554 about?
NCT01698554 is a clinical study titled "Bimatoprost in the Treatment of Eyelash Hypotrichosis". This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).
What is the current status of trial NCT01698554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2012-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01698554?
The interventions under investigation include: bimatoprost formulation A solution (DRUG), bimatoprost solution 0.03 % (DRUG), vehicle of bimatoprost formulation A solution (DRUG), vehicle of bimatoprost solution 0.03 % (DRUG).
Who is sponsoring clinical trial NCT01698554?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01698554's enrollment target sits among peer trials
464 821st of 2000 higher than 1,180 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia